AcquisitionOther
Pyxis Oncology, Inc. acquired Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Pyxis Oncology, Inc. -> Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate · $0.64
1 “This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfizer, and expands our
Open source record (SEC) ↗